Exact Sciences (EXAS) Q3 Revenues Beat
Tweet
Share
E-mail
Get Alerts EXAS Hot Sheet
Price: $104.91 --0%
Financial Fact:
Net loss per share-basic and diluted (in dollars per share): -0.36
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Net loss per share-basic and diluted (in dollars per share): -0.36
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Exact Sciences (NASDAQ: EXAS) reported Q3 EPS of ($1.46), which may not compare to the analyst estimate of ($0.52). Revenue for the quarter came in at $408.4 million versus the consensus estimate of $337.37 million. COVID-19 testing revenue was $102.2 million.
For earnings history and earnings-related data on Exact Sciences (EXAS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Vireo Growth completes acquisition of C21 Investments
- Ross Stores, Inc. (ROST) PT Raised to $240 at Bernstein SocGen Group
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
